Research programme: microRNA therapeutics - GlaxoSmithKline/Regulus TherapeuticsAlternative Names: miR-122 inhibitors - GlaxoSmithKline/Regulus; miR-146 inhibitors - GlaxoSmithKline/Regulus; miR-155 inhibitors - GlaxoSmithKline/Regulus; miR-181a inhibitors - GlaxoSmithKline/Regulus
Latest Information Update: 11 Jul 2014
At a glance
- Originator Regulus Therapeutics LLC
- Developer GlaxoSmithKline; Regulus Therapeutics
- Class MicroRNAs
- Mechanism of Action MicroRNA inhibitors; MIRN122 microRNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis C; Inflammation